Orbactiv (oritavancin) is an intravenously administered drug treating ABSSSI infections caused by susceptible bacteria such as Staphylococcus aureus, MRSA, Streptococcus species and Enterococcus faecalis, according to a news release.
This is the third antibacterial drug the FDA has approved this year to treat ABSSSI. Dalvance (dalbavancin) was approved in May and Sivextro (tedizolid) was approved in June, according to the news release.
Orbactiv was designated as a Qualified Infectious Disease Product due to its intention to treat serious or life-threatening infection. Due to its designation, the drug was given priority review, including an expedited review of its application.
More articles on the FDA:
Quicker FDA drug approval leads to increased drug withdrawals
What the latest FDA guidance means for mHealth
FDA proposes exempting certain devices from premarket requirements
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
